Neurogene: Genes over ERT for monogenic CNS diseases

Why Neurogene is developing gene therapies for two monogenic CNS diseases

Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn't been explored.

Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by autosomal recessive AGA mutations that lead to toxic accumulation of N-acetylglucosamines and cellular dysfunction in multiple tissue and cell types, including neurons. The

Read the full 543 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE